CONSTELLATION TECHNOLOGIES LIMITED — Regulatory Filings 2007

Sep 26, 2007

==> picture [97 x 76] intentionally omitted <==

27 September 2007

Mr Rohan Abeyewardene Australian Stock Exchange Level 5 Riverside Centre 123 Eagle Street BRISBANE QLD 4000

Fax : (07) 3832 4114 Email : Rohan.Abeyewardene@asx.com.au

Dear Mr Abeyewardene

In response to your query of 26 September 2007 in relation to the price and volume increases of Agenix securities, we advise the following:

1. The Company is not aware of any information concerning it that has not been announced which, if known, could be an explanation for today’s trading in the securities of the Company.

2. Not applicable.

3. The Company is not aware of specific reasons. Possible explanations could be:

   • a. On 21 September 2007 the Company announced the commencement of the ThromboView Phase II Pulmonary Embolism trial in the United States and Canada. Data from this trial will be shared with potential partners. There has been an awareness of the potential value of ThromboView for some time. However, the commencement of the Phase II trial demonstrates that the Company has made considerable advances in relation to the regulatory and manufacturing aspects of the programme.

   • b. The Company has previously advised, including in its Prospectus released on 16 April 2007 , its expectation that it would receive market launch approval in the second half of calendar year 2007 in China from the State Food and Drug Administration (“SFDA”) for YouHeDing, the anti-hepatitis B virus drug, the rights to which were acquired with the recent acquisitions of its Chinese operations via SHRG and YSY. These acquisitions have been extensively covered in the Company’s previous announcements and releases. Furthermore, the Company has announced on several occasions that it expects to be deriving revenue from sales of YouHeDing in the second half of 2007. The SFDA has already approved the clinical trial and manufacturing aspects of YouHeDing’s development. Market launch approval has not yet been received.

   • c. It should be further noted that the Company share price has reached as high as 30 cents within the last three months.

115798v1c

==> picture [97 x 76] intentionally omitted <==

1. Confirmed. The Company considers that it is in compliance with the Listing Rules and in particular, Listing Rule 3.1.

If any further information is required, please contact our office.

Yours faithfully

==> picture [155 x 48] intentionally omitted <==

Karl Schlobohm Company Secretary Agenix Limited

115798v1c

==> picture [105 x 96] intentionally omitted <==

ASX Limited ABN 98 008 624 691 Level 5 Riverside Centre 123 Eagle Street Brisbane QLD 4000

26 September 2007

Mr Karl Schlobohm Company Secretary Agenix Ltd 11 Durbell Street ACACIA RIDGE QLD 4110

PO Box 7055 Riverside Centre Brisbane QLD 4001

Telephone 61 (07) 3835 4004 Facsimile 61 (07) 3832 4114 Internet http://www.asx.com.au

By Email: kschlobohm@prosperityadvisers.com.au

Dear Karl

Agenix Ltd (the “Company”) RE: PRICE QUERY

We have noted a change in the price of the Company’s securities from a close of 15.5 cents on 24 September 2007 to a high of 22 cents today. We have also noted an increase in the volume of trading in the securities over this period.

In light of the price change and increase in volume, please respond to each of the following questions.

1. Is the Company aware of any information concerning it that has not been announced which, if known, could be an explanation for recent trading in the securities of the Company?

2. If the answer to question 1 is yes, can an announcement be made immediately? If not, why not and when is it expected that an announcement will be made?

Please note, if the answer to question 1 is yes and an announcement cannot be made immediately, you need to contact us to discuss this and you need to consider a trading halt (see below).

1. Is there any other explanation that the Company may have for the price change and increase in volume in the securities of the Company?

2. Please confirm that the Company is in compliance with the listing rules and, in particular, listing rule 3.1.

Your response should be sent to me by e-mail at rohan.abeyewardene@asx.com.au or by facsimile on facsimile number (07) 3832 4114. It should not be sent to the Company Announcements Office.

Unless the information is required immediately under listing rule 3.1, a response is requested as soon as possible and, in any event, not later than 9.00 a.m. E.S.T. tomorrow, Thursday, 27 September 2007.

AGX2007.09.26pq-rma

Page 1 of 2

Under listing rule 18.7A, a copy of this query and your response will be released to the market, so your response should be in a suitable form and separately address each of the questions asked. If you have any queries or concerns, please contact me immediately.

Listing rule 3.1

Listing rule 3.1 requires an entity to give ASX immediately any information concerning it that a reasonable person would expect to have a material effect on the price or value of the entity’s securities. The exceptions to this requirement are set out in listing rule 3.1A.

In responding to this letter you should consult listing rule 3.1 and Guidance Note 8 – Continuous Disclosure: listing rule 3.1.

If the information requested by this letter is information required to be given to ASX under listing rule 3.1 your obligation is to disclose the information immediately.

Your responsibility under listing rule 3.1 is not confined to, or necessarily satisfied by, answering the questions set out in this letter.

Trading halt

If you are unable to respond by the time requested, or if the answer to question 1 is yes and an announcement cannot be made immediately, you should consider a request for a trading halt in the Company’s securities. As set out in listing rule 17.1 and Guidance Note 16 – Trading Halts we may grant a trading halt at your request. We may require the request to be in writing. We are not required to act on your request. You must tell us each of the following.

• The reasons for the trading halt.

• How long you want the trading halt to last.

• The event you expect to happen that will end the trading halt.

• That you are not aware of any reason why the trading halt should not be granted.

• Any other information necessary to inform the market about the trading halt, or that we ask for.

The trading halt cannot extend past the commencement of normal trading on the second day after the day on which it is granted. If a trading halt is requested and granted and you are still unable to reply to this letter before the commencement of trading, suspension from quotation would normally be imposed by us from the commencement of trading if not previously requested by you. The same applies if you have requested a trading halt because you are unable to release information to the market, and are still unable to do so before the commencement of trading.

If you have any queries regarding any of the above, please let me know.

Yours sincerely

==> picture [185 x 63] intentionally omitted <==

Rohan Abeyewardene Adviser, Issuers (Brisbane)

AGX2007.09.26pq-rma

Page 2 of 2